Showing 1 - 5 results of 5 for search 'Bruna Oriol-Tordera', query time: 0.03s Refine Results
  1. 1
    Impact of ChAdOx1 or DNA Prime Vaccination on Magnitude, Breadth, and Focus of MVA-Boosted Immunogen-Specific T Cell Responses

    Impact of ChAdOx1 or DNA Prime Vaccination on Magnitude, Breadth, and Focus of MVA-Boosted Immunogen-Specific T Cell Responses by Alex Olvera, Luis Romero-Martin, Bruna Oriol-Tordera, Miriam Rosas-Umbert, Tuixent Escribà, Beatriz Mothe, Christian Brander

    Published 2024-03-01
    Get full text
    Article
  2. 2
    Plasma proteomic profiling identifies CD33 as a marker of HIV control in natural infection and after therapeutic vaccinationResearch in context

    Plasma proteomic profiling identifies CD33 as a marker of HIV control in natural infection and after therapeutic vaccinationResearch in context by Clara Duran-Castells, Anna Prats, Bruna Oriol-Tordera, Anuska Llano, Cristina Galvez, Javier Martinez-Picado, Ester Ballana, Edurne Garcia-Vidal, Bonaventura Clotet, Jose A. Muñoz-Moreno, Thomas Hanke, José Moltó, Beatriz Mothe, Christian Brander, Marta Ruiz-Riol

    Published 2023-09-01
    Get full text
    Article
  3. 3
    Methylation regulation of Antiviral host factors, Interferon Stimulated Genes (ISGs) and T-cell responses associated with natural HIV control.

    Methylation regulation of Antiviral host factors, Interferon Stimulated Genes (ISGs) and T-cell responses associated with natural HIV control. by Bruna Oriol-Tordera, Maria Berdasco, Anuska Llano, Beatriz Mothe, Cristina Gálvez, Javier Martinez-Picado, Jorge Carrillo, Julià Blanco, Clara Duran-Castells, Carmela Ganoza, Jorge Sanchez, Bonaventura Clotet, Maria Luz Calle, Alex Sánchez-Pla, Manel Esteller, Christian Brander, Marta Ruiz-Riol

    Published 2020-08-01
    Get full text
    Article
  4. 4
    IRF7 expression correlates with HIV latency reversal upon specific blockade of immune activation

    IRF7 expression correlates with HIV latency reversal upon specific blockade of immune activation by Ifeanyi Jude Ezeonwumelu, Edurne García-Vidal, Eudald Felip, Eudald Felip, Maria C. Puertas, Maria C. Puertas, Bruna Oriol-Tordera, Lucía Gutiérrez-Chamorro, André Gohr, Marta Ruiz-Riol, Marta Ruiz-Riol, Marta Massanella, Marta Massanella, Bonaventura Clotet, Bonaventura Clotet, Bonaventura Clotet, Javier Martinez-Picado, Javier Martinez-Picado, Javier Martinez-Picado, Javier Martinez-Picado, Roger Badia, Eva Riveira-Muñoz, Ester Ballana

    Published 2022-09-01
    Get full text
    Article
  5. 5
    Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome

    Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome by Bruna Oriol-Tordera, Anna Esteve-Codina, María Berdasco, Míriam Rosás-Umbert, Elena Gonçalves, Clara Duran-Castells, Francesc Català-Moll, Anuska Llano, Samandhy Cedeño, Maria C. Puertas, Martin Tolstrup, Ole S. Søgaard, Bonaventura Clotet, Javier Martínez-Picado, Tomáš Hanke, Behazine Combadiere, Roger Paredes, Dennis Hartigan-O'Connor, Manel Esteller, Michael Meulbroek, María Luz Calle, Alex Sanchez-Pla, José Moltó, Beatriz Mothe, Christian Brander, Marta Ruiz-Riol

    Published 2022-04-01
    Get full text
    Article

Search Tools: